menu search

SCNLF / Scancell to speak at prestigious vaccine event

Scancell to speak at prestigious vaccine event
Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF), which is developing immunotherapies for cancer and infectious disease, said its chief executive and chief scientific officer, Professor Lindy Durrant, will present at the 2023 World Vaccine Congress Europe, currently underway in Barcelona. Durrant said:  "Following the recent announcement of positive data from the first stage in our phase II SCOPE trial with SCIB1 cancer vaccine for advanced melanoma, I am excited to join other leading experts in the field to discuss the ongoing clinical progress of our two lead cancer vaccine assets SCIB1/iSCIB-1+ and Modi-1 at this prestigious forum within the vaccine community. Read More
Posted: Oct 18 2023, 03:14
Author Name: Proactive Investors
Views: 110545

SCNLF News  

Scancell melanoma trial data chosen for poster presentation at SITC

By Proactive Investors
November 1, 2023

Scancell melanoma trial data chosen for poster presentation at SITC

Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) told investors that it has been selected for a poster presentation of data from the first stage of its Pha more_horizontal

Scancell makes strong progress with lead immunotherapy assets

By Proactive Investors
October 31, 2023

Scancell makes strong progress with lead immunotherapy assets

Key highlights for biotech group Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF)'s financial year ending April 30 included a positive data reading arising more_horizontal

Scancell to speak at prestigious vaccine event

By Proactive Investors
October 18, 2023

Scancell to speak at prestigious vaccine event

Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF), which is developing immunotherapies for cancer and infectious disease, said its chief executive and chie more_horizontal

Scancell trial results back strong value prospects - broker

By Proactive Investors
September 19, 2023

Scancell trial results back strong value prospects - broker

Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF)'s expectation-busting initial results from the phase II SCOPE trial in advanced melanoma backs Stifel's vi more_horizontal


Search within

Pages Search Results: